

**Oxford Immunotec Global PLC**  
**Condensed consolidated statements of operations**  
(unaudited)

(in thousands, except share and per share data)	Three months ended September 30,		Nine months ended September 30,	
	2015	2014	2015	2014
Revenue				
Product .....	\$ 8,310	\$ 6,480	\$ 22,045	\$ 19,192
Service .....	9,634	6,845	23,952	18,195
Total revenue .....	17,944	13,325	45,997	37,387
Cost of revenue				
Product .....	3,757	2,944	9,712	8,807
Service .....	4,312	3,568	11,514	9,710
Total cost of revenue .....	8,069	6,512	21,226	18,517
Gross profit.....	9,875	6,813	24,771	18,870
Operating expenses:				
Research and development .....	3,187	1,946	8,392	4,185
Sales and marketing .....	7,381	7,468	22,549	18,376
General and administrative .....	4,137	3,567	11,788	11,447
Total operating expenses .....	14,705	12,981	42,729	34,008
Loss from operations .....	(4,830)	(6,168)	(17,958)	(15,138)
Other income (expense):				
Interest expense, net .....	(19)	(41)	(53)	(104)
Foreign exchange gains (losses) .....	476	76	(33)	(331)
Other (expense) income .....	(64)	91	50	170
Loss before income taxes .....	(4,437)	(6,042)	(17,994)	(15,403)
Income tax expense .....	46	53	94	79
Net loss .....	\$ (4,483)	\$ (6,095)	\$ (18,088)	\$ (15,482)
Net loss per share attributable to ordinary shareholders—basic and diluted .....	\$ (0.20)	\$ (0.35)	\$ (0.84)	\$ (0.89)
Weighted-average shares used to compute net loss attributable to ordinary shareholders—basic and diluted .....	22,259,840	17,333,441	21,619,375	17,300,881

**Reconciliation of net loss to Adjusted EBITDA**  
(unaudited)

(in thousands)	Three months ended September 30,		Nine months ended September 30,	
	2015	2014	2015	2014
Net loss .....	\$ (4,483)	\$ (6,095)	\$ (18,088)	\$ (15,482)
Income tax expense .....	46	53	94	79
Interest expense, net .....	19	41	53	104
Depreciation and amortization .....	597	479	1,533	1,239
EBITDA .....	(3,821)	(5,522)	(16,408)	(14,060)
Reconciling items:				
Share-based compensation expense .....	994	734	2,582	1,759
Unrealized exchange losses (gains) .....	422	(164)	(193)	3
Loss on change in fair value of warrants .....	—	—	—	22
Change in fair value of contingent purchase price consideration .....	52	38	148	38
Intangible asset impairment charge .....	385	—	385	—
Adjusted EBITDA .....	\$ (1,968)	\$ (4,914)	\$ (13,486)	\$ (12,238)

**Oxford Immunotec Global PLC**  
**Condensed consolidated balance sheets**  
(unaudited)

(in thousands, except share and per share data)	September 30, 2015	December 31, 2014
<b>Assets</b>		
Current assets:		
Cash and cash equivalents .....	\$ 88,483	\$ 50,165
Restricted cash .....	112	200
Accounts receivable, net .....	7,444	6,823
Inventory .....	6,473	6,425
Prepaid expenses and other .....	2,718	2,755
<b>Total current assets .....</b>	<b>105,230</b>	<b>66,368</b>
Restricted cash, non-current .....	80	192
Property and equipment, net .....	5,706	4,537
In-process research and development .....	1,832	2,399
Goodwill .....	46	50
Other intangible assets, net .....	278	273
Other assets .....	19	30
<b>Total assets .....</b>	<b>\$ 113,191</b>	<b>\$ 73,849</b>
<b>Liabilities and shareholders' equity</b>		
Current liabilities:		
Accounts payable .....	\$ 3,213	\$ 2,368
Accrued liabilities .....	7,886	7,070
Deferred income .....	1,686	1,993
Current portion of loans payable .....	127	137
Taxes payable .....	147	—
<b>Total current liabilities .....</b>	<b>13,059</b>	<b>11,568</b>
Long-term portion of loans payable .....	352	454
Contingent purchase price consideration .....	1,274	1,218
<b>Total liabilities .....</b>	<b>14,685</b>	<b>13,240</b>
<b>Shareholders' equity:</b>		
Ordinary shares, £0.006705 nominal value; 36,183,293 shares authorized at September 30, 2015 and December 31, 2014, and 22,538,047 and 17,614,650 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively .....	242	192
Additional paid-in capital .....	243,126	186,816
Accumulated deficit .....	(139,917)	(121,829)
Accumulated other comprehensive loss .....	(4,945)	(4,570)
<b>Total shareholders' equity .....</b>	<b>98,506</b>	<b>60,609</b>
<b>Total liabilities and shareholders' equity .....</b>	<b>\$ 113,191</b>	<b>\$ 73,849</b>